Haisco Pharmaceutical Group: BD-led growth lifted 9M revenue 50.61% and attributable net income 314.01% YoY

What happened

Haisco Pharmaceutical Group reported a 50.61% rise in nine-month revenue to ¥4.97bn and a 314.01% rise in attributable net income to ¥1.376bn year over year. Adjusted net income grew 263.22%, and research and development expense rose 67.98%.

Confirmed

Global impact / market context

Profit rose much faster than sales because business development receipts, which are upfront payments from partners, and collaboration sales added income beyond drug sales. Higher research spending shows the company is reinvesting in its pipeline, which could support future revenue but raises costs.

Analyst inference

The results show licensing deals can sharply lift reported profit at a Chinese drugmaker, even as core research spending climbs. Investors weighing the stock would compare repeatable drug sales with one-time deal payments, since deal income may not recur each period.

Analyst inference

What to watch

1. Research and development expense rose 67.98%, so watch whether this spending continues at a similar pace and whether it eventually produces new drugs or partnership deals. Confirmed
2. Haisco could disclose the size and timing of future business development deals, which would help show whether licensing income is repeatable or tied to one-time payments. Proposed
3. Watch the split between drug sales and collaboration sales in later reports, because a heavy reliance on deal receipts could make profit less steady across periods. Analyst inference

Evidence

• Original source link unavailable